Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group's first NOC approval in Canada.

Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.

ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad. Varenicline tablets had annual sales of 15 mn Canadian dollar in Canada (IQVIA MAT December 2024).

Shares of Zdyus Lifesciences Limited was last trading in BSE at Rs. 935.50 as compared to the previous close of Rs. 945.35. The total number of shares traded during the day was 100291 in over 3610 trades.

The stock hit an intraday high of Rs. 951.40 and intraday low of 931.40. The net turnover during the day was Rs. 94665501.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals NOC HealthCanada ZDSVareniclineTablets